Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s KRAS Race: Homegrown Contenders Play Catch-Up

Gaining On In-Licensed Assets

Executive Summary

The sizzling race for China’s first approved KRAS inhibitor has seen Amgen/BeiGene’s Lumakras drop out and Mirati/Zai Lab’s Krazati lag in a confirmatory Phase III trial, while domestic fast-followers are in the meantime eyeing their first approval filings by the end of this year.

You may also be interested in...



Chinese-Language Podcast: IPOs, 阿斯利康和跨国药企本土化3.0,KRAS研发进展

Recent trending topics in the China biopharma sphere include three biotech IPOs in Hong Kong and Shanghai, the reported possible spin off of AstraZeneca's China operations, and the changing development landscape for KRAS inhibitors.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Lilly’s latest acquisition; the outlook for Stelara biosimilars; better biomarkers needed in the TIGIT/PD-1 combo field?; Sanofi on the deal-making landscape; and the shifting KRAS race in China.

Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price

Krazati was approved for second-line NSCLC with labeling that positions it ahead of Lumakras on efficacy, but not safety. Pricing is slightly higher than for Amgen’s drug.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel